Journal article

Value of risk-directed thromboprophylaxis in ambulatory lung and gastrointestinal cancer care: Economic evaluation of the TARGET-TP randomized trial.

Marliese Alexander, Antonio Ahumada-Canale, Kate Hadfield, Dan Liu, Michael Michael, Jeanne Tie, Benjamin J Solomon, Samuel J Harris, Craig R Underhill, Richard De Abreu Lourenço, Kate Burbury

Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2026

DOI: 10.1200/jco.2026.44.16_suppl.12137

Abstract

12137 Background: Thromboembolism (TE) is a major and preventable hematological complication in patients with cancer, contributing to substantial adverse health impacts for patients and the health system. Targeted Thromboprophylaxis in Ambulatory Patients Receiving Anticancer Therapies (TARGET-TP; ACTRN12618000811202) was an Australian phase III randomized trial of biomarker risk-directed enoxaparin thromboprophylaxis. The TARGET-TP intervention reduced TE (HR 0.31, p = 0.005) and six-month mortality (HR 0.48, p = 0.03) versus usual care (no prophylaxis). This study evaluated the value for money of the TARGET-TP in..

View full abstract

Keywords

3 Good Health and Well Being
Comparative Effectiveness Research
32 Biomedical and Clinical Sciences
Cost Effectiveness Research
Prevention
3211 Oncology and Carcinogenesis
Health Services
Cancer
Clinical Trials and Supportive Activities
Clinical Research
Hematology